Dr. Christopher Schaber, President and CEO of Soligenix, a company developing drug therapies in rare diseases and areas of unmet medical need, including a treatment for oral mucositis in head and neck […]
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is currently an unmet medical need. Soligenix is a biotherapeutic business segment dedicated to […]
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief […]
Soligenix’s self-described “DOM–INNATE” study has initiated patient enrollment. The late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that patient […]
Dr. Christopher Schaber is the President and CEO of Soligenix, a late stage biopharmaceutical company with a pipeline of pharmaceutical products to treat a variety of rare diseases with an unmet […]
